We and others have previously shown that testosterone replacement therapy (TRT) results in sustained weight loss in the majority of middle-aged hypogonadal men. Previously, however, a small proportion failed to lose at least 5% of their baseline weight. The reason for this is not yet understood. In the present study, we sought to identify early indicators that may predict successful long-term weight loss, defined as a reduction of at least 5% of total body weight relative to baseline weight (T0), in men with hypogonadism undergoing TRT. Eight parameters measured were assessed as potential predictors of sustained weight loss: loss of 3% or more of baseline weight after 1 year of TU treatment, severe hypogonadism, BMI, waist circumference, International Prostate Symptom Score (IPSS), glycated hemoglobin (HbA1C), age and use of vardenafil. Among the eight measured parameters, three factors were significantly associated with sustained weight loss over the entire period of TU treatment: (1) a loss of 3% of the baseline body weight after 1 year of TRT; (2) baseline BMI over 30; and (3) a waist circumference >102 cm. Age was not a predictor of weight loss.
The aging male : the official journal of the International Society for the Study of the Aging Male. 2017 Jan 13 [Epub ahead of print]
Mahmoud Salman, Dany-Jan Yassin, Huda Shoukfeh, Joanne Elisabeth Nettleship, Aksam Yassin
a Institute of Urology and Andrology , Norderstedt-Hamburg , Germany., b Dresden International University, Department of Preventive Medicine, Men's Health Program , Dresden , Germany , and., c Department of Human Metabolism , University of Sheffield , Sheffield , UK.